CL2021002374A1 - Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg) - Google Patents
Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg)Info
- Publication number
- CL2021002374A1 CL2021002374A1 CL2021002374A CL2021002374A CL2021002374A1 CL 2021002374 A1 CL2021002374 A1 CL 2021002374A1 CL 2021002374 A CL2021002374 A CL 2021002374A CL 2021002374 A CL2021002374 A CL 2021002374A CL 2021002374 A1 CL2021002374 A1 CL 2021002374A1
- Authority
- CL
- Chile
- Prior art keywords
- egcg
- fibroids
- vitamin
- treatment
- agent
- Prior art date
Links
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title abstract 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title abstract 3
- 229940030275 epigallocatechin gallate Drugs 0.000 title abstract 3
- 206010046798 Uterine leiomyoma Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 201000010260 leiomyoma Diseases 0.000 title abstract 2
- 229940046008 vitamin d Drugs 0.000 title abstract 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 abstract 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 abstract 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 abstract 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 235000005487 catechin Nutrition 0.000 abstract 1
- 229950001002 cianidanol Drugs 0.000 abstract 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al uso de vitamina D y un agente seleccionado del grupo que consiste en: galato de epigalocatequina (EGCG), catequina, galocatequina y galato de epicatequina (ECG), para la prevención, control y/o tratamiento de fibromas en un sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000003843A IT201900003843A1 (it) | 2019-03-15 | 2019-03-15 | Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002374A1 true CL2021002374A1 (es) | 2022-04-18 |
Family
ID=66690890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002374A CL2021002374A1 (es) | 2019-03-15 | 2021-09-10 | Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg) |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20220160734A1 (es) |
| EP (1) | EP3937927B1 (es) |
| KR (1) | KR20210139390A (es) |
| CN (1) | CN113573706B (es) |
| AR (1) | AR118372A1 (es) |
| BR (1) | BR112021018308A2 (es) |
| CA (1) | CA3130592A1 (es) |
| CL (1) | CL2021002374A1 (es) |
| CO (1) | CO2021011789A2 (es) |
| EA (1) | EA202192524A1 (es) |
| ES (1) | ES2981336T3 (es) |
| GE (1) | GEP20247615B (es) |
| HR (1) | HRP20240970T1 (es) |
| HU (1) | HUE067061T2 (es) |
| IT (1) | IT201900003843A1 (es) |
| JO (1) | JOP20210222A1 (es) |
| MA (1) | MA55281A (es) |
| MX (1) | MX2021010491A (es) |
| PE (1) | PE20220130A1 (es) |
| PL (1) | PL3937927T3 (es) |
| RS (1) | RS65682B1 (es) |
| SG (1) | SG11202108937VA (es) |
| SM (1) | SMT202400180T1 (es) |
| UA (1) | UA127910C2 (es) |
| UY (1) | UY38608A (es) |
| WO (1) | WO2020187729A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202200011114A1 (it) * | 2022-05-26 | 2023-11-26 | Recordati Ind Chimica E Farmaceutica S P A | “uso dell’associazione tadalafil e vitamina d3 per la preparazione di un prodotto per il trattamento orale della ipertrofia prostatica benigna e relativi metodi produttivi” |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| KR20010006027A (ko) | 1997-04-03 | 2001-01-15 | 포인트 바이오메디칼 코퍼레이션 | 방광내 약물 송달 시스템 |
| US20050032741A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin Compositions |
| US7910138B2 (en) * | 2003-10-09 | 2011-03-22 | Medigene Ag | Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin |
| US8221803B1 (en) * | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
| CN102670584A (zh) * | 2011-03-18 | 2012-09-19 | 江苏凯吉生物科技有限公司 | 没食子儿茶素没食子酸酯在制备抗良性前列腺增生药物中的应用 |
| CN105029406A (zh) * | 2015-04-14 | 2015-11-11 | 劲膳美生物科技股份有限公司 | 子宫肌瘤医学配方食品 |
| AU2016247674A1 (en) * | 2015-04-14 | 2017-10-19 | Atossa Genetics Inc. | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
| CN104856996B (zh) * | 2015-04-27 | 2018-01-05 | 南京舒鹏生物科技有限公司 | 吡咯喹啉醌、其衍生物和/或盐新的药用用途以及药用组合物 |
| CN105054025B (zh) * | 2015-08-09 | 2017-11-14 | 青岛大学附属医院 | 一种用于炎症性肠病患者的低脂低渗低渣型肠内营养粉剂 |
| WO2017132775A1 (en) * | 2016-02-05 | 2017-08-10 | Viteava Pharmaceuticals Inc. | Novel compositions and methods for the treatment of leiomyoma |
| WO2023099763A1 (en) * | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
-
2019
- 2019-03-15 IT IT102019000003843A patent/IT201900003843A1/it unknown
-
2020
- 2020-03-13 EA EA202192524A patent/EA202192524A1/ru unknown
- 2020-03-13 EP EP20710518.0A patent/EP3937927B1/en active Active
- 2020-03-13 UY UY0001038608A patent/UY38608A/es not_active Application Discontinuation
- 2020-03-13 HR HRP20240970TT patent/HRP20240970T1/hr unknown
- 2020-03-13 WO PCT/EP2020/056799 patent/WO2020187729A1/en not_active Ceased
- 2020-03-13 SG SG11202108937VA patent/SG11202108937VA/en unknown
- 2020-03-13 UA UAA202104915A patent/UA127910C2/uk unknown
- 2020-03-13 MX MX2021010491A patent/MX2021010491A/es unknown
- 2020-03-13 GE GEAP202015739A patent/GEP20247615B/en unknown
- 2020-03-13 MA MA055281A patent/MA55281A/fr unknown
- 2020-03-13 BR BR112021018308A patent/BR112021018308A2/pt unknown
- 2020-03-13 CA CA3130592A patent/CA3130592A1/en active Pending
- 2020-03-13 SM SM20240180T patent/SMT202400180T1/it unknown
- 2020-03-13 US US17/439,168 patent/US20220160734A1/en not_active Abandoned
- 2020-03-13 KR KR1020217033446A patent/KR20210139390A/ko not_active Ceased
- 2020-03-13 PL PL20710518.0T patent/PL3937927T3/pl unknown
- 2020-03-13 HU HUE20710518A patent/HUE067061T2/hu unknown
- 2020-03-13 PE PE2021001522A patent/PE20220130A1/es unknown
- 2020-03-13 CN CN202080021135.XA patent/CN113573706B/zh active Active
- 2020-03-13 RS RS20240732A patent/RS65682B1/sr unknown
- 2020-03-13 ES ES20710518T patent/ES2981336T3/es active Active
- 2020-03-16 AR ARP200100727A patent/AR118372A1/es unknown
-
2021
- 2021-08-12 JO JOP/2021/0222A patent/JOP20210222A1/ar unknown
- 2021-09-08 CO CONC2021/0011789A patent/CO2021011789A2/es unknown
- 2021-09-10 CL CL2021002374A patent/CL2021002374A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3937927A1 (en) | 2022-01-19 |
| HUE067061T2 (hu) | 2024-09-28 |
| KR20210139390A (ko) | 2021-11-22 |
| UY38608A (es) | 2020-10-30 |
| CA3130592A1 (en) | 2020-09-24 |
| CN113573706A (zh) | 2021-10-29 |
| US20220160734A1 (en) | 2022-05-26 |
| JOP20210222A1 (ar) | 2021-08-12 |
| IT201900003843A1 (it) | 2020-09-15 |
| SG11202108937VA (en) | 2021-09-29 |
| PL3937927T3 (pl) | 2024-09-02 |
| GEP20247615B (en) | 2024-03-25 |
| PE20220130A1 (es) | 2022-01-27 |
| ES2981336T3 (es) | 2024-10-08 |
| CO2021011789A2 (es) | 2021-09-20 |
| MA55281A (fr) | 2022-01-19 |
| CN113573706B (zh) | 2025-02-07 |
| SMT202400180T1 (it) | 2024-07-09 |
| UA127910C2 (uk) | 2024-02-07 |
| EA202192524A1 (ru) | 2021-11-19 |
| WO2020187729A1 (en) | 2020-09-24 |
| BR112021018308A2 (pt) | 2021-11-23 |
| AR118372A1 (es) | 2021-09-29 |
| EP3937927B1 (en) | 2024-04-17 |
| EP3937927C0 (en) | 2024-04-17 |
| HRP20240970T1 (hr) | 2024-10-25 |
| MX2021010491A (es) | 2021-10-01 |
| RS65682B1 (sr) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016176279A8 (en) | Uses of cannabidiol for treatment of infantile spasms | |
| BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
| BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| BR112017016072A2 (pt) | ?composição, curativo de ferida, e, método de fabricação de uma composição? | |
| BR112015007131A2 (pt) | métodos para melhorar o efeito de egcg em atenuar a perda muscular esquelética | |
| AR119043A1 (es) | Métodos para acelerar la cicatrización mediante el uso de composiciones cannabinoides | |
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| BR112017026025A2 (pt) | composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer | |
| BR112018016729A2 (pt) | novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase | |
| BR112022002289A2 (pt) | Composições de curativo líquido e seus usos veterinários | |
| MX2020006443A (es) | Combinacion de un retinoide y un extracto de silybum marianum (l.) gaertn. | |
| BRPI1100012A2 (pt) | agente para realçar a expressão de fatores associados com redox | |
| MX367321B (es) | Composición para el cuidado de la piel y métodos para la misma. | |
| CL2021002374A1 (es) | Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg) | |
| GB2566235A (en) | A novel formulation for rapid wound healing and control of infection | |
| BR112018011021A2 (pt) | método para inativar xenoantígenos em tecidos biológicos | |
| EP3403656A4 (en) | COMPOSITION FOR PREVENTING, HEALING OR TREATING THE FEMALE CLIMATE SYNDROME WITH LOGANINE OR DERIVATIVES THEREOF AS AN ACTIVE SUBSTANCE | |
| MX375916B (es) | Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito. | |
| IN2015KN00370A (es) | ||
| PH12019502145A1 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient | |
| UA130333C2 (uk) | Композиції, які містять кромогліцієву кислоту, для лікування дерматиту | |
| PH12022552013A1 (en) | Novel medicament for treating hepatic encephalopathy | |
| GB2583234A (en) | Compositions including pine bark extract, berryfruit extract and a source of l-theanine and uses thereof | |
| NZ732032A (en) | Compositions comprising l-theanine, proanthocyanidin(s) and a catechin and uses thereof | |
| MX2021005573A (es) | Uso del compuesto cannabinoide en el tratamiento de la neurodermatitis. |